Stock Events

Stock Events

BioNexus Gene Lab 

$2.14
0
+$0+0% Wednesday 06:55

Statistics

Day High
2.15
Day Low
2.13
52W High
-
52W Low
-
Volume
2,399
Avg. Volume
-
Mkt Cap
3.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-16.8%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
19.02MRevenue
-3.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGLC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides integrated sequencing and array-based solutions for genetic and genomic analysis, directly competing in the gene sequencing space with BioNexus Gene Lab.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the genetic engineering and modification sector, offering alternative or complementary technologies to those of BioNexus Gene Lab.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading genome editing company that competes with BioNexus Gene Lab in the development of therapeutics based on gene editing technologies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the CRISPR gene editing space, making it a competitor by offering gene editing technologies and therapies that may overlap with or rival those of BioNexus Gene Lab.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies, competing with BioNexus Gene Lab in the genomic analysis and sequencing market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in genetic sequencing and the development of medications based on genetic insights, positioning it as a competitor in the genetic research and therapeutic development space.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in the creation of drugs based on genetic insights, making it a competitor in the field of genetic disease treatment and research.
Teladoc Health
TDOC
Mkt Cap1.53B
Teladoc Health, through its acquisition of Livongo and other initiatives, is expanding into the genetic health advice and telemedicine space, indirectly competing with BioNexus Gene Lab's genetic analysis services.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health specializes in cancer diagnostics through liquid biopsies, competing in the genetic testing market, particularly in the oncology segment.

About

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Show more...
CEO
ISIN
US0906283066

Listings

XNAS
US
BGLC
BOATS
BOATS
BGLC.BOATS

0 Comments

Share your thoughts

FAQ

What is BioNexus Gene Lab stock price today?▼
The current price of BGLC.BOATS is $2.14 USD — it has increased by +0% in the past 24 hours. Watch BioNexus Gene Lab stock price performance more closely on the chart.
What is BioNexus Gene Lab stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioNexus Gene Lab stocks are traded under the ticker BGLC.BOATS.
What is BioNexus Gene Lab market cap?▼
Today BioNexus Gene Lab has the market capitalization of 3.84M
What is BioNexus Gene Lab revenue for the last year?▼
BioNexus Gene Lab revenue for the last year amounts to 19.02M USD.
What is BioNexus Gene Lab net income for the last year?▼
BGLC.BOATS net income for the last year is -3.2M USD.
When did BioNexus Gene Lab complete a stock split?▼
BioNexus Gene Lab has not had any recent stock splits.